136 related articles for article (PubMed ID: 16878407)
21. Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology.
Märten A; Büchler MW; Werft W; Wente MN; Kirschfink M; Schmidt J
J Immunother; 2010; 33(2):219-24. PubMed ID: 20139773
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic juice cytology in the diagnosis of intraductal papillary mucinous neoplasm of the pancreas: significance of sampling by peroral pancreatoscopy.
Yamaguchi T; Shirai Y; Ishihara T; Sudo K; Nakagawa A; Ito H; Miyazaki M; Nomura F; Saisho H
Cancer; 2005 Dec; 104(12):2830-6. PubMed ID: 16287152
[TBL] [Abstract][Full Text] [Related]
23. Limitations in improving detection of pancreatic adenocarcinoma.
Mendieta Zerón H; García Flores JR; Romero Prieto ML
Future Oncol; 2009 Jun; 5(5):657-68. PubMed ID: 19519205
[TBL] [Abstract][Full Text] [Related]
24. [Early cancer of the exocrine pancreas: diagnosis and prognosis].
Gall FP; Kessler H
Chirurg; 1987 Feb; 58(2):78-83. PubMed ID: 3568819
[TBL] [Abstract][Full Text] [Related]
25. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
26. [Detection and prognosis of small pancreatic ductal adenocarcinoma].
Ariyama J
Nihon Geka Gakkai Zasshi; 1997 Jul; 98(7):592-6. PubMed ID: 9276864
[TBL] [Abstract][Full Text] [Related]
27. Intraductal papillary mucinous neoplasms of the pancreas: performance of pancreatic fluid analysis for positive diagnosis and the prediction of malignancy.
Maire F; Voitot H; Aubert A; Palazzo L; O'Toole D; Couvelard A; Levy P; Vidaud M; Sauvanet A; Ruszniewski P; Hammel P
Am J Gastroenterol; 2008 Nov; 103(11):2871-7. PubMed ID: 18775021
[TBL] [Abstract][Full Text] [Related]
28. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
[TBL] [Abstract][Full Text] [Related]
29. Improved early diagnosis of cystadenocarcinoma of the pancreas.
Wu H; Cheng NS; Zhang YG; Luo HZ; Yan LN; Li J
Hepatobiliary Pancreat Dis Int; 2007 Feb; 6(1):87-91. PubMed ID: 17287173
[TBL] [Abstract][Full Text] [Related]
30. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
31. Preoperative differential diagnosis of benign and malignant pancreatic lesions--the value of pancreatic secretory trypsin inhibitor, procarboxypeptidase B, CA19-9 and CEA.
Cerwenka H; Aigner R; Quehenberger F; Werkgartner G; Bacher H; Hauser H; Mischinger HJ
Hepatogastroenterology; 1997; 44(16):1117-21. PubMed ID: 9261609
[TBL] [Abstract][Full Text] [Related]
32. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
Hámori J; Arkosy P; Lenkey A; Sápy P
Acta Chir Hung; 1997; 36(1-4):125-7. PubMed ID: 9408313
[TBL] [Abstract][Full Text] [Related]
33. [Diagnosis and differential diagnosis of pancreatic carcinoma].
Mössner J
Praxis (Bern 1994); 1997 Mar; 86(10):397-400. PubMed ID: 9173496
[TBL] [Abstract][Full Text] [Related]
34. Elevated tumor marker CA 19-9 in the differential diagnosis of pancreatic mass lesions.
Cwik G; Wallner G; Skoczylas T; Krzyzanowski M; Ciechainski A; Madro P
Ann Univ Mariae Curie Sklodowska Med; 2004; 59(2):213-8. PubMed ID: 16146081
[TBL] [Abstract][Full Text] [Related]
35. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH
Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811
[TBL] [Abstract][Full Text] [Related]
36. Progress in the diagnosis and treatment of pancreatic cancer--the Kyoto University experience.
Manabe T; Tobe T
Hepatogastroenterology; 1989 Dec; 36(6):431-6. PubMed ID: 2693297
[TBL] [Abstract][Full Text] [Related]
37. [Early detection of pancreatic cancer by serum markers].
Nakae Y; Naruse S; Shibata T; Kitagawa M; Kondo T; Hayakawa T; Kuno N; Kurimoto K
Rinsho Byori; 1994 Feb; 42(2):139-42. PubMed ID: 7511183
[TBL] [Abstract][Full Text] [Related]
38. Serum tumor markers and cyst fluid analysis are useful for the diagnosis of pancreatic cystic tumors.
Sperti C; Pasquali C; Guolo P; Polverosi R; Liessi G; Pedrazzoli S
Cancer; 1996 Jul; 78(2):237-43. PubMed ID: 8673998
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis and management of pancreatic cancer.
De La Cruz MS; Young AP; Ruffin MT
Am Fam Physician; 2014 Apr; 89(8):626-32. PubMed ID: 24784121
[TBL] [Abstract][Full Text] [Related]
40. [Current strategy to cure pancreatic cancer].
Tanaka M
Nihon Geka Gakkai Zasshi; 2002 Mar; 103(3):290-3. PubMed ID: 11968759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
